By vgreene, 22 August, 2019 BRAF mutation testing: only if testing informs clinical trial participation1,2
By vgreene, 22 August, 2019 BRAF mutation testing:1,2 mandatory for pts for whom BRAF-directed tx may be an option
By vgreene, 22 August, 2019 HER2 status:1,2 to identify candidates for trastuzumab, pertuzumab, or lapatinib
By vgreene, 21 August, 2019 Option 2: Combine abnormalities identified via molecular and cytogenetic analyses
By vgreene, 21 August, 2019 Option 2: Combine abnormalities identified via molecular and cytogenetic analyses
By vgreene, 21 August, 2019 Option 1: Separate abnormalities identified via molecular vs. cytogenetic analyses